A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Condition | Intervention |
---|---|
Cryptosporidiosis HIV Infections |
Drug: Diclazuril |
Study Type: | Interventional |
Study Design: | Primary Purpose: Treatment |
Official Title: | 28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) |
Ages Eligible for Study: | 12 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Zidovudine (AZT).
- Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more.
- Aerosolized pentamidine.
- Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril.
- Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug.
- Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol.
Patients must have the following:
Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.
- Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up).
Prior Medication:
Allowed:
- Diclazuril.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Uncontrolled vomiting.
- Estimated survival less than 28 days.
- Other treatable enteric pathogens must be treated and eradicated prior to study entry.
Concurrent Medication:
Excluded:
- Amphotericin B.
- Other antibiotics or antiprotozoal drugs.
- Other investigational agents.
- Trimethoprim/sulfamethoxazole.
- Antifungal medications except nystatin.
- Ganciclovir for other than Cytomegalovirus (CMV) retinitis.
- Antidiarrheal agents other than patients on long term loperamide prior to study entry.
Patients with the following are excluded:
- Undependable in following the instructions of the investigator.
- Not able to swallow capsules.
- Uncontrolled vomiting.
- Estimated survival less than 28 days.
Prior Medication:
Excluded:
- Diclazuril within 2 weeks of study entry.
United States, New York | |
Bellevue Hosp / New York Univ Med Ctr | |
New York, New York, United States, 10016 | |
Cornell Univ Med Ctr | |
New York, New York, United States, 10021 | |
Saint Luke's - Roosevelt Hosp Ctr | |
New York, New York, United States, 10025 |
No publications provided
ClinicalTrials.gov Identifier: | NCT00002278 History of Changes |
Other Study ID Numbers: | 038B, JRD 64,433/1102 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections Cryptosporidiosis Diarrhea |
diclazuril Coccidiostats Acquired Immunodeficiency Syndrome |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Cryptosporidiosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Intestinal Diseases, Parasitic Parasitic Diseases |
Protozoan Infections, Animal Parasitic Diseases, Animal Coccidiosis Protozoan Infections Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Diclazuril Coccidiostats Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on March 07, 2013